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Table 1 Cost data sources
Item Cost sources
Drugs German Rote Liste 2013, web-based research
Ambulatory medical
treatment
German value measurement (EBM 2000+)
and fee regulations for doctors (GOÄ)
Non-pharmacological
therapies
According to agreements between
German health insurance funds and
professional organizations
Medical devices / aids Web-based research
Hospitalisation and
Rehabilitation
German Diagnosis-Related Groups (G-DRG),
web- and phone-based research




Average payments according to German
retirement insurance














































































































































































All values are means (± standard deviation) or number of patients (%)
Table 3 Overview of antispastic therapies and measures during
the study
IncobotulinumtoxinA group:
















31 (28.7 %) 23 (32.4 %) 20 (20.2 %) 18 (19.1 %)
Physical
therapy
60 (55.6 %) 54 (52.9 %) 54 (54.5 %) 51 (54.3 %)
Occupational
therapy
43 (39.8 %) 42 (41.2 %) 41 (41.4 %) 44 (46.8 %)
Speech
therapy
10 (9.3 %) 8 (7.8 %) 8 (8.1 %) 9 (8.6 %)
Other
therapies
3 (2.8 %) 6 (6.0 %) 4 (4.0 %) 4 (4.3 %)
Therapeutic
aids
12 (11.0 %) 5 (5.7 %) - 1 (1.0 %)
Conventional therapy group:















67 (60.9 %) 66 (67.3 %) 63 (69.2 %) 58 (69.0 %)
Physical
therapy
68 (61.8 %) 59 (60.2 %) 54 (54.5 %) 52 (61.9 %)
Occupational
therapy
15 (13.6 %) 11 (11.2 %) 11 (12.1 %) 8 (9.5 %)
Speech
therapy
5 (4.6 %) 5 (5.1 %) 5 (5.5 %) 4 (4.8 %)
Other
therapies
3 (2.7 %) 5 (5.1 %) - 1 (1.2 %)
Therapeutic
aids
10 (11.0 %) 8 (8.2 %) 12 (13.2 %) 8 (9.5 %)
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Table 5 Overview of total costs by cost centers (in €)
INCO n = 93 CON n = 83








Medical devices / aids 79 12
Nursing home care 3,089 2,203
Total direct costs 8,188 3,806
Reduction in earning capacity 2,081 988
Total costs 10,268 4,794
Table 4 Responder analyses at study end after 1-year of treatment








56.4 73.9 62.9 15.5 <0.01 <0.01 <0.01
Shoulder abduction 65.5 100 73.0 19.7 <0.01 <0.01 <0.01
Shoulder elevation 66.7 88.9 72.7 20.6 <0.01 <0.01 <0.01
Flexed elbow 78.3 92.9 83.8 26.9 <0.01 <0.01 <0.01
Forearm pronation 81.4 73.7 79.0 22.0 <0.01 <0.01 <0.01
Flexed wrist 82.1 94.7 86.2 26.6 <0.01 <0.01 <0.01
Thumb-in-palm 77.8 81.3 78.8 20.0 <0.01 <0.01 <0.01
Clenched fist 79.1 95.2 84.4 22.2 <0.01 <0.01 <0.01
Intrinsic-plus-position
of the hand
73.3 100 78.9 19.5 <0.01 <0.01 <0.01
Responder rates (%); response was definded as ≥ 1-point improvement on the Ashworth Scale for all treated muscle groups at study end; Fisher´s exact test was
used for group comparisons
Table 6 Overview of Cost-utility ratios and ICER
Utility parameter INCO CON
Responder rate in Ashworth Score per clinical pattern Responder rate Cost-utility ratio Responder rate Cost-utility ratio ICER
Shoulder adduction / internal rotation 62.9 % 16,325 € 15.5 % 30,929 € 11,549 €
Shoulder abduction 73.0 % 14,066 € 19.7 % 24,335 € 10,271 €
Shoulder elevation 72.7 % 14,124 € 20.6 % 23,272 € 10,507 €
Flexed elbow 83.8 % 12,253 € 26.9 % 17,821 € 9,621 €
Pronated forearm 79.0 % 12,998 € 22.0 % 21,791 € 9,604 €
Flexed wrist 86.2 % 11,912 € 26.6 % 18,022 € 9,185 €
Thumb-in-palm 78.8 % 13,031 € 20.0 % 23,970 € 9,310 €
Clenched fist 84.4 % 12,166 € 22.2 % 21,595 € 8,801 €
Intrinsic-Plus-position (hand) 78.9 % 13,014 € 19.5 % 24,585 € 9,216 €
Improvement in SF-12 dimension Improvement Cost-utility ratio Improvement Cost-utility ratio ICER
Physical Health 7.96 1,290 € 0.83 5,776 € 768 €
Mental Health 10.75 955 € 5.71 840 € 1,086 €
Incremental Cost-Effectiveness Ratio (ICER) = (Total costs INCO – Total costs CON)/(Utility value INCO – Utility value CON)
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